ConductScience.org, home

Paper29617739

Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660-A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection.

Dubberke ER and 5 others. Clin Infect Dis, 2018. Cited by 119 papers, by iCite.

Cite this record

ConductScience Library. Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660-A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection. Papers, record 29617739. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29617739

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660-A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection.
PubMed
Journal
Clin Infect Dis
PubMed
Year
2018
PubMed
Publication types
Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
119
iCite
Relative citation ratio, by iCite
4.67
iCite
Revised in PubMed
2022-04-08
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Dubberke ERErik R
2Lee CHChristine H
3Orenstein RRobert
4Khanna SSahil
5Hecht GGail
6Gerding DNDale N

Source PubMed

Download CSV of authors

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-Bacterial AgentsMajor topic
Biological TherapyMajor topic
Clostridioides difficileMajor topic
Clostridium InfectionsMajor topic
Enterocolitis, PseudomembranousMajor topic
MicrobiotaMajor topic
Adolescent
Adult
Aged
Aged, 80 and over
Diarrhea
Double-Blind Method
Feces
Female
Humans
Male
Middle Aged
Recurrence
Treatment Outcome
Young Adult

Source PubMed

Download CSV of topics

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT02299570Microbiota Restoration Therapy for Recurrent Clostridium Difficile InfectionDerived from the trialYesClinicalTrials.gov
NCT03817125Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome InterventionBackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections2

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in30084881Reply to Million et al.https://conductscience.org/library/papers/30084881PubMed
Comment in30084939Bacterial Cocktail to Treat Clostridium difficile Infection: Primum Non Nocere.https://conductscience.org/library/papers/30084939PubMed

Download CSV of comments and corrections

Cited by70

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 119 citations.

PMIDTitleJournalYearIn PapersSource
42332289Klebsiella genus as driver of human disease: from infections to non-communicable disorders.Nat Rev Microbiol2026https://conductscience.org/library/papers/42332289PubMed
42286373Efficacy Outcomes of Fecal Microbiota, Live-jslm in Preventing Recurrent Clostridioides difficile Infection from Seven Clinical Studies.Infect Dis Ther2026https://conductscience.org/library/papers/42286373PubMed
42042323Newer Therapeutics to Selectively Kill Clostridioides difficile and Restore the Microbiome.Infect Dis Rep2026https://conductscience.org/library/papers/42042323PubMed
41809590
Randomized double-blind clinical trial evaluating the effectiveness and safety of secondary prophylaxis with oral vancomycin versus placebo in the prevention of recurrence of clostridioides difficile infection in patients receiving systemic antibiotic therapy (PREVAN trial).
JAC Antimicrob Resist2026https://conductscience.org/library/papers/41809590PubMed
41653256Safety and Efficacy of Fecal Microbiota, Live-jslm for Prevention of Recurrent Clostridioides difficile Infection Among Hospitalized Participants in PUNCH CD3-OLS.Infect Dis Ther2026https://conductscience.org/library/papers/41653256PubMed
41530607Fecal Microbiota Transplantation in 2025: Two Steps Forward, One Step Back.Curr Gastroenterol Rep2026https://conductscience.org/library/papers/41530607PubMed
41454672The role of gut microbiome in aging-associated diseases: where do we stand now and how technology will transform the future.Gut Microbes2026https://conductscience.org/library/papers/41454672PubMed
41245385Integrated analysis of the safety of fecal microbiota, live-jslm in adults with recurrent Clostridioides difficile infection from five prospective clinical trials: an update.Ther Adv Gastroenterol2025https://conductscience.org/library/papers/41245385PubMed
41239747Development of Peptide Glucosyltransferase Inhibitors With Comprehensive Coverage Across Clostridioides difficile Toxin B Sub-Types.Biotechnol Bioeng2026https://conductscience.org/library/papers/41239747PubMed
41230019Prevention of recurrent Clostridioides difficile infection by fecal microbiota, live-jslm (REBYOTA®) administered via colonoscopy: 6-month data from the single-arm phase IIIb CDI-SCOPE trial.Ther Adv Gastroenterol2025https://conductscience.org/library/papers/41230019PubMed
41158525Mechanisms of Clostridioides difficile glucosyltransferase toxins and their roles in pathology: insights and emerging therapeutic strategies.Front Cell Infect Microbiol2025https://conductscience.org/library/papers/41158525PubMed
40984900Microbiota-Based Therapies for Recurrent Clostridium difficile Infection: A Systematic Review of Their Efficacy and Safety.Cureus2025https://conductscience.org/library/papers/40984900PubMed
40901203Fecal microbiota transplantation as a therapeutic modality for recurrent Clostridioides difficile infection: reviewing efficacy, safety, mechanisms of action, and outcomes.Ann Med Surg (Lond)2025https://conductscience.org/library/papers/40901203PubMed
40619813Integrative systems biology approaches for analyzing microbiome dysbiosis and species interactions.Brief Bioinform2025https://conductscience.org/library/papers/40619813PubMed
40321366
Safety and effectiveness of fecal microbiota, live-jslm (REBYOTA®) administered by colonoscopy for prevention of recurrent Clostridioides difficile infection: 8-week results from CDI-SCOPE, a single-arm, phase IIIb trial.
Ther Adv Gastroenterol2025https://conductscience.org/library/papers/40321366PubMed
40177588
Safety and Efficacy of Fecal Microbiota, Live-jslm, in Preventing Recurrent Clostridioides difficile Infection in Participants Who Were Mildly to Moderately Immunocompromised in the Phase 3 PUNCH CD3-OLS Study.
Open Forum Infect Dis2025https://conductscience.org/library/papers/40177588PubMed
40142848Operationalizing Team Science at the Academic Cancer Center Network to Unveil the Structure and Function of the Gut Microbiome.J Clin Med2025https://conductscience.org/library/papers/40142848PubMed
40046540Antibiotic-Associated Diarrhea Beyond C. Difficile: A Scoping Review.Brown J Hosp Med2023https://conductscience.org/library/papers/40046540PubMed
39944364Causal role of the gut microbiome in certain human diseases: a narrative review.eGastroenterology2024https://conductscience.org/library/papers/39944364PubMed
39821840Management of Recurrent Clostridioides difficile Infection (rCDI): A Systematic Literature Review to Assess the Feasibility of Indirect Treatment Comparison (ITC).Infect Dis Ther2025https://conductscience.org/library/papers/39821840PubMed

See all 70 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/29617739

GET https://conductscience.org/api/papers/v1/29617739/cited_by?page=2